Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Evobrutinib TF2 vs TF1
NCT04314024Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evobrutinib in multiple sclerosis (MS) (6 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration Under Fasted Conditions at Day 6, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity Under Fasted Conditions at Day 6 and 4 more. Started May 2020; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04314024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314024.